Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE03 in PTSD Patients With Sleep Disturbances
NCT06685965Phase 2Completed
- Sponsor
- Reconnect Labs
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine in post-traumatic stress disorder (PTSD), sleep disorder, Insomnia, sponsored by Reconnect Labs. Started Sep 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
post-traumatic stress disorder (PTSD)sleep disorderInsomnia
Beyond the preview
Go deeper on NCT06685965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685965.